Please use this identifier to cite or link to this item:
Title: Amygdalar CB2 cannabinoid receptor mediates fear extinction deficits promoted by orexin-A/hypocretin-1
Author: Ten Blanco, Marc
Flores, África
Pereda Pérez, Inmaculada
Piscitelli, Fabiana
Izquierdo Luengo, Cristina
Cristino, Luigia
Romero, Julián
Hillard, Cecilia J.
Maldonado, Rafael
Marzo, Vincenzo di
Berrendero, Fernando
Keywords: Cànnabis
Issue Date: 1-May-2022
Publisher: Elsevier
Abstract: Anxiety and stress disorders are often characterized by an inability to extinguish learned fear responses. Orexins/ hypocretins are involved in the modulation of aversive memories, and dysregulation of this system may contribute to the aetiology of anxiety disorders characterized by pathological fear. The mechanisms by which orexins regulate fear are unknown. Here we investigated the role of the endogenous cannabinoid system in the impaired fear extinction induced by orexin-A (OXA) in male mice. The selective inhibitor of 2-arachidonoylglycerol (2-AG) biosynthesis O7460 abolished the fear extinction deficits induced by OXA. Accordingly, increased 2AG levels were observed in the amygdala and hippocampus of mice treated with OXA that do not extinguish fear, suggesting that high levels of this endocannabinoid are related to poor extinction. Impairment of fear extinction induced by OXA was associated with increased expression of CB2 cannabinoid receptor (CB2R) in microglial cells of the basolateral amygdala. Consistently, the intra-amygdala infusion of the CB2R antagonist AM630 completely blocked the impaired extinction promoted by OXA. Microglial and CB2R expression depletion in the amygdala with PLX5622 chow also prevented these extinction deficits. These results show that overactivation of the orexin system leads to impaired fear extinction through 2-AG and amygdalar CB2R. This novel mechanism could be of relevance for the development of novel potential approaches to treat diseases associated with inappropriate retention of fear, such as post-traumatic stress disorder, panic anxiety and phobias.
Note: Reproducció del document publicat a:
It is part of: Biomedicine & Pharmacotherapy, 2022, vol. 149
Related resource:
ISSN: 0753-3322
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
722805.pdf3.54 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons